A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.
Dr Noor Abuhadra discusses the various first-line treatment options for metastatic TNBC, highlighting the importance of PDL1 expression for immunotherapy and germline testing for targeted therapies like PARP inhibitors. Patient Shay Elkins shares her treatment journey, from her initial chemo and immunotherapy to surgical intervention, emphasizing the importance of a collaborative approach with her healthcare team and the supportive role of nursing staff.
First-line treatment with the combination of motixafortide, cemiplimab-rwlc, gemcitabine, and nab-paclitaxel elicited responses in patients with metastatic pancreatic adenocarcinoma, according to initial data from the pilot portion of a phase 2 trial.